Jim Simons Oncocyte Corp Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.2 - $0.35 $15,700 - $27,475	78,500 Added 131.71%	138,100 $32,000
Q1 2023 May 12, 2023	BUY	$0.2 - $0.49 $6,280 - $15,386	31,400 Added 111.35%	59,600 $21,000
Q4 2022 Feb 13, 2023	BUY	$0.25 - $15.6 $7,050 - $439,920	28,200 New	28,200 $9,000
Q2 2022 Aug 12, 2022	SELL	$0.86 - $1.53 $135,407 - $240,898	-157,450 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.15 - $2.25 $12,017 - $23,512	-10,450 Reduced 6.22%	157,450 $235,000
Q4 2021 Feb 11, 2022	BUY	$2.04 - $3.59 $226,440 - $398,490	111,000 Added 195.08%	167,900 $364,000
Q3 2021 Nov 12, 2021	SELL	$3.53 - $5.89 $66,011 - $110,143	-18,700 Reduced 24.74%	56,900 $203,000
Q2 2021 Aug 13, 2021	SELL	$3.77 - $6.0 $130,819 - $208,200	-34,700 Reduced 31.46%	75,600 $434,000
Q1 2021 May 13, 2021	BUY	$2.39 - $6.5 $263,617 - $716,950	110,300 New	110,300 $572,000
Q3 2020 Nov 13, 2020	SELL	$1.2 - $1.89 $89,640 - $141,183	-74,700 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.91 - $3.45 $142,677 - $257,715	74,700 New	74,700 $143,000
Q2 2019 Aug 12, 2019	SELL	$2.49 - $5.45 $339,138 - $742,290	-136,200 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$1.47 - $5.91 $200,214 - $804,942	136,200 New	136,200 $538,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $246M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.